Medical Director Hematology Research US Oncology / McKesson Specialty Health
Oncology
Dr. Jeff P. Sharman, MD
|
|
Give Review
Dr. Jeff P. Sharman practices Oncology. He went to medical school at University of California Davis School of Medicine. University of California Davis School of Medicine is ranked 43 in research and 19 in primary care medicine He over the years received 1 awards: "Meaningful Use Stage 1 Certification". Jeff Sharman has written publications. He has 13 publications published with PubMed. The lastest publication is: 'An open-label phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in chronic lymphocytic leukemia.' Jeff Sharman is registered with Medicare.
Publications
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
- An open-label phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in chronic lymphocytic Leukemia.
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.
- Objective responses in relapsed T-cell Lymphomas with single agent brentuximab vedotin.
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic Lymphoma: an open-label, multicentre, phase 1b/2 trial.
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-Cell malignancies.
- B-cell signaling networks reveal a negative prognostic human Lymphoma cell subset that emerges during tumor progression.
- Effectiveness of warfarin among patients with Cancer.
- Gemcitabine-associated thrombotic microangiopathy.
- Engagement of CD81 induces ezrin tyrosine phosphorylation and its Cellular redistribution with filamentous actin.
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic Leukemia.
Schools
University of California At Irvine California College of Medicine amp Surgery
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Massachusetts General Hospital -
University of California Davis School of Medicine
Drug Facts
| NPI NUMBER | 1659596179 | |
| NPPES Provider LastName | SHARMAN | |
| NPPES Provider FirstName | JEFF | |
| NPPES Provider ZIPCode | 943055101 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1280.0 | |
| Distinct Opioid Count | 8.0 | |
| Opioid Claim Count | 218.0 | |
| Percent Opioid Claims | 17.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659596179 |
| Last Name Of The Provider | SHARMAN |
| First Name Of The Provider | JEFF |
| View All |
Similar Doctors
|
|
Dr. Peter A. Kovach, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Caton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel P. Kerrigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deven L. Smith, MD
This Doctor is OpenDoctor Recommended.
|